NewsBenzingaHC Wainwright & Co. mantiene recomendación de compra sobre Immix Biopharma y eleva el precio objetivo a 27 dólares HC Wainwright & Co. mantiene recomendación de compra sobre Immix Biopharma y eleva el precio objetivo a 27 dólares Benzinga 2026.11.16 12:29 (GMT+0) Open on Benzinga Other news HKMA, Swift Explore Cross-Border Tokenized Payments FirstSource Stock Outlook: Is Wall Street Bullish or Bearish? What Are Wall Street Analysts' Target Price for Alliant Energy Stock? Public Service Enterprise Stock: Analyst Estimates & Ratings Are Wall Street Analysts Bullish on FirstEnergy Stock? DuPont de Nemours Stock: Is Wall Street Bullish or Bearish?